Oral Drug Delivery Videos

  1. Pharmaceutical Spray Drying: Sustainable Commercial Best Practices

    Learn more about defining the spray drying process with an emphasis on specific enhancements to accommodate scale-up to commercial scale equipment of challenging applications or molecules.

  2. Becoming A Combination Product Development Organization 1/12/2026

    In this segment of the Drug Delivery Leader Live online event, Eying The Drug Delivery Regulatory Landscape: The 'Must See' Watch List For 2026, Chief Editor Tom von Gunden asks the panel to comment on regulatory challenges and considerations for traditional drug product pharma companies moving into combination product development. Patient centricity, device expertise, and supplier relationships are among the topics identified.

  3. Rapid, Material-Sparing Feasibility Screening For Hot Melt Extrusion

    Discover a screening process to quickly assess HME feasibility that yields more accurate predictions for API loading and degradation while saving material and time compared to traditional approaches.

  4. Enabling Oral Delivery Of Biologics With Vivtex's Thomas von Erlach 4/7/2026

    The rapidly expanding demand for biologics-based treatments for chronic, metabolic diseases has spurred a desire for oral administration. Videocast host Tom von Gunden talks with CEO Thomas von Erlach from delivery platform developer Vivtex about using high-throughput screening, advanced computational tools, and formulation technologies to drive higher absorption and bioavailability of peptides and other macromolecules delivered via gastrointestinal routes. 

  5. Increasing Oral Delivery Precision For CNS Targets With Tris Pharma's Ketan Mehta 5/13/2026

    Videocast host Tom von Gunden talks with CEO Ketan Mehta of Tris Pharma about innovations in oral delivery approaches to CNS disorders, such as ADHD, pain, and addiction. They discuss dosage form options, including liquid, solid, and powder, for leveraging polymer-based particle science to deliver stable, long-acting formulations. Among the advances discussed is precision targeting of payload release locations in the GI tract for optimal absorption.

  6. What Is the Impact of the New QMSR on 21 CFR Part 4? 7/11/2024

    In this segment of the Drug Delivery Leader Live event New FDA QMSR: Its Role in Part 4 Compliance for Combination Products, DDL Executive Editor Fran DeGrazio enlists consultants Laurie Auerbach of Compliance Prodigies and Ed Bills of Edwin Bills Consultant to summarize where Part 4 is documented in the new guidance.

  7. Formulation Of Crystalline Nanoparticles Enabling Superior Drug Load 8/13/2024

    Explore how bioavailability of poorly soluble APIs can be improved and patient compliance enhanced by reducing the size or number of tablets that a patient must take to achieve the required dose.

  8. Who Is Responsible For Design Controls? 7/11/2024

    In this segment of the Drug Delivery Leader Live event New FDA QMSR: Its Role in Part 4 Compliance for Combination Products, DDL Executive Editor Fran DeGrazio asks consultants Laurie Auerbach of Compliance Prodigies and Ed Bills of Edwin Bills Consultant to identify which organization in a combination product manufacturing process are responsible for design controls – the sponsor company, the contracted component provider, or both.

  9. What Happened to CAPA (Corrective and Preventive Actions) Requirements? 7/11/2024

    Is CAPA still part of the requirements picture for the new QMSR? In this segment of the Drug Delivery Leader Live event New FDA QMSR: Its Role in Part 4 Compliance for Combination Products, consultant Ed Bills of Edwin Bills Consultant discusses changes in the treatment of corrective and preventive actions.

  10. The History And Evolution Of Drug Delivery Technologies 5/23/2025

    In this segment of the Drug Delivery Leader Live online event, Innovations In Drug Delivery: Opportunities For Enhancing Familiar, Mature Approaches, Carolyn Dorgan, director of technical services at device design consultancy Suttons Creek, and James Wabby, head of global regulatory affairs for emerging device technologies and combination products at AbbVie, trace the evolution of drug delivery technologies over the last 100 or so years. The timeline illustrates the trajectory from the earliest prefilled syringes to the nanotechnologies and other advances of today.